Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Nobelpharma CEO Says Sakigake System “Very Helpful”
March 17, 2016
- PMDA Had 43 Advanced Regulatory Advisory Sessions with Startups, Academia in FY2015
March 16, 2016
- Vaccine Panel Wary about Including Synflorix in Public Immunization Program
March 16, 2016
- Oculomucocutaneous Syndrome, Erythema Multiforme Added to ADR List for Halaven
March 16, 2016
- MHLW to Require CTD-Based Submissions for Generics, Effective March 2017
March 15, 2016
- Sales Thresholds for Re-Pricing Rule to Be Key Point of Future Discussions: MHLW Pharma Management Director
March 15, 2016
- MHLW Panel Launches Discussions on New Basic Plan against Cancer
March 14, 2016
- MHLW Panel Roughly OKs Use of MID-NET Database by Drug Makers
March 14, 2016
- No Licensing Deal Clinched for First AMED-Backed Drug Seed
March 14, 2016
- MHLW’s Info Gathering System for Pediatric Drugs Goes Live
March 14, 2016
- Japan to Lead Initiatives to Disseminate Regulatory Submission, Review Rules in APEC
March 14, 2016
- MHLW Wants to Continue Price Maintenance Scheme for On-Patent Drugs: Shiozaki
March 11, 2016
- Shiozaki Seeks Understanding for “Huge-Seller” Drug Re-Pricing
March 11, 2016
- Drug Makers Should Have Freewheeling Discussions towards 2018 Reform, MHLW Wants to Pick Their Brains: Official
March 10, 2016
- “Huge Seller” Re-Pricing Dominates Discussions at LDP Study Group
March 10, 2016
- 76 Products Join Japanese Pharmacopoeia: MHLW
March 10, 2016
- Difficult to Enact Clinical Research Bill in Current Diet Session: LDP Health Panel Chief
March 9, 2016
- PMDA Aims to Complete Reviews for 70% of Priority Products within 9 Months in FY2016
March 9, 2016
- MHLW Sorts Out Schemes for Humanitarian Trials, Patient-Initiated Mixed Care
March 8, 2016
- 77.8% of Generics Converge into Single Price Brand in FY2016 Revision: MHLW
March 7, 2016
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…